Summit Therapeutics Inc. Increase (Decrease) in Other Noncurrent Liabilities
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Other Noncurrent Liabilities of -$30.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-07-23
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was $3.00K, a 88.89% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was -$33.00K, a 232.00% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$2.00K, a 108.00% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was $30.00K, a 25.00% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $80.00K, a 15.79% decline from fiscal 2024.
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was $95.00K.
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 3 month as first filed | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | -$30.00K 10-Q · filed 2026-07-23 | -$32.00K derived: sum of 3 quarters · filed 2026-07-23 | -$2.00K derived: sum of 4 quarters · filed 2026-07-23 | |
| 2026-03-31 | -$33.00K 10-Q · filed 2026-04-30 | -$35.00K derived: sum of 2 quarters · filed 2026-04-30 | -$5.00K derived: sum of 3 quarters · filed 2026-04-30 | $22.00K derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $28.00K derived: sum of 2 quarters · filed 2026-02-23 | $55.00K derived: sum of 3 quarters · filed 2026-07-23 | $80.00K 10-K · filed 2026-02-23 | |
| 2025-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $57.00K derived: sum of 2 quarters · filed 2026-07-23 | $82.00K 10-Q · filed 2025-10-20 | $107.00K derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $52.00K 10-Q · filed 2026-07-23 | $77.00K derived: sum of 3 quarters · filed 2026-07-23 | $101.00K derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-03-31 | $25.00K 10-Q · filed 2026-04-30 | $50.00K derived: sum of 2 quarters · filed 2026-04-30 | $74.00K derived: sum of 3 quarters · filed 2026-04-30 | -$1.62M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $49.00K derived: sum of 2 quarters · filed 2026-02-23 | -$1.65M derived: sum of 3 quarters · filed 2026-02-23 | $95.00K 10-K · filed 2026-02-23 | |
| 2024-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | -$1.67M derived: sum of 2 quarters · filed 2025-10-20 | $70.00K 10-Q · filed 2025-10-20 | $12.00K derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | -$1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $46.00K 10-Q · filed 2025-08-11 | -$12.00K derived: sum of 3 quarters · filed 2026-02-23 | $46.00K derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $1.74M 10-Q · filed 2025-05-01 | $1.76M 10-Q · filed 2024-05-01 | $1.68M derived: sum of 2 quarters · filed 2026-02-23 | $1.74M derived: sum of 3 quarters · filed 2026-02-23 | $1.74M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2023-09-30 | $58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $58.00K derived: sum of 2 quarters · filed 2024-10-30 | $58.00K 10-Q · filed 2024-10-30 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |